(80) concluded that sclerostin antibody therapy reversed the adverse effects of T2D on bone mass and strength in rats and improved bone defect regeneration, suggesting that sclerostin could be used as a biomarker for early detection of osteoporosis in diabetes patients. This evidence concerns the gene SOST and osteoporosis.